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Abstract The proper concentrations of plasma bioelements
may favorably reduce the incidence of metabolic disorders,
which often occur during immunosuppressive therapy.
Mycophenolate mofetil (MMF) is currently one of the most
frequently administered immunosuppressive agents; how-
ever, MMF treatment is often related to gastrointestinal side
effects. The aim of this study was thus to verify whether the
MMF treatment itself, or its metabolite pharmacokinetics,
has an effect on the concentrations of plasma bioelements.
To determine this, the effect of MMF on the levels of both
major (sodium [Na], potassium [K], calcium [Ca], magne-
sium [Mg]), and trace (iron [Fe], zinc [Zn], copper [Cu])
plasma bioelements in 61 renal transplant recipients was
assessed in comparison to a control group (n=45). The
pharmacokinetic parameters of mycophenolic acid were
determined by the high-performance liquid chromatography
method. All patients filled out a 24-h diet history
questionnaire. The results showed high plasma concen-
trations of Fe and low plasma concentrations of Mg and Zn
as compared with diagnostic norms. The patients treated
with MMF had significantly lower plasma Na (P<0.001)
and significantly higher plasma Zn (P=0.030) and Cu
concentrations (P<0.001). In conclusion, MMF treatment
was found to affect plasma Fe, Zn, and Cu levels by
increasing their concentrations while decreasing the plasma
Na concentration. Mg and Zn deficiencies, as well as
excessive Fe levels, are frequently observed irrespective of
the immunosuppressive regimen applied, which suggests
that monitoring of these bioelements may be favorable.
Keywords Mycophenolate mofetil.Major elements.
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Introduction
Successful renal transplantation is chiefly achieved by
suppression of the process of transplant rejection. In clinical
transplantology, different immunosuppressive regimens are
applied, among which corticosteroids and calcineurin
inhibitors (CNI) (cyclosporine [CsA] and tacrolimus
[Tac]), as well as mycophenolate mofetil (MMF), are the
most common agents [1]. Secondly, it is known that
adequate nutritional status may improve the post-
transplant outcomes, as malnutrition is one of the main
complications in the late post-transplant period. Proper
concentrations of plasma bioelements may favorably reduce
the incidence of metabolic disorders, which frequently
occur during immunosuppressive therapy [2].
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tive MMF is rapidly and entirely hydrolyzed into an active
metabolite, mycophenolic acid (MPA). MPA is a non-
nucleoside, uncompetitive, reversible inosine monophos-
phate dehydrogenase inhibitor which prevents acute rejec-
tion of the transplanted organ and also decreases the
frequency of late rejection after 1 year and consecutive
years [3, 4].
It has been shown that MMF administration is not
associated with increases in lipid levels, neurotoxicity, or
nephrotoxicity, and neither does it affect blood pressure. In
addition, MMF administration allows reduction of CsA and
Tac doses both of which demonstrate nephrotoxicity [5, 6].
However, MMF therapy is often associated with gastroin-
testinal side effects such as diarrhea, nausea, vomiting,
abdominal pain, and gastrointestinal bleeding [7]. Over
20% of patients treated with MMF suffer from anemia [8,
9]. Therapies consisting of CsA and Tac administration may
also be accompanied by diarrhea and vomiting [10], which
decreases the bioavailability of nutritional components such
as the mineral elements.
So far, there have been some studies describing the
influence of CNI on the concentration of some mineral
elements; however, little research has been done to evaluate
the influence of MMF on the concentrations of major
(calcium [Ca], magnesium [Mg], potassium [K], sodium
[Na]), and trace (copper [Cu], iron [Fe], zinc [Zn]) plasma
bioelements. As MMF is known for frequent gastrointesti-
nal disorders, the aim of this study was to determine
whether MMF treatment or MPA pharmacokinetics influ-
ences plasma bioelements in renal transplant recipients.
Materials and Methods
Study Population
This study considered 106 renal transplant patients aged
20–72 years (mean, 46±13 years), treated with different
immunosuppressive regimens. All patients were in the late
post-transplant period (>6 months) and the transplants were
performed in the period 1996–2008. The characteristics of
the patients are presented in Table 1.
Of the 106 renal transplant recipients, 61 patients (aged
23–69 years; mean, 43±12 years) were included in the
study group as they had been treated with MMF-based
immunosuppressive regimens. MMF was administered in
combination with CsA (n=28) or Tac (n=24), or without
CNI (n=9). Almost all patients in the study group were
treated with corticosteroids (88.5%).
The control group consisted of 45 renal transplant
recipients aged 20–72 years who had been treated with
Table 1 Characteristics of patients included in the study
Study group (n=61) Control group (n=45) All patients (n=106)
Mean±SD
Age (year) 43±12* 49±13* 46±13
Post-transplant period (year) 4.7±2.9* 6.6±3.1* 5.5±3.1
Body weight (kg) 74.9±16.7 70.0±13.6 72.9±15.6
BMI (kg/m
2) 25.9±4.7 24.8±4.1 25.5±4.5
Creatinine concentration (mg/dL) 1.80±0.69 1.76±0.74 1.78±0.70
Creatinine clearance (mL/min) 58.4±24.4 51.5±19.7 55.5±22.7
Alanine aminotransferase (U/L) 32.1±19.5 30.9±17.9 31.8±19.0
Asparagine aminotransferase (U/L) 25.7±9,8 26.0±10.3 25.8±9.9
Number of patients
Sex (male/female) 34/27* 19/26* 53/53
CsA/Tac 28/24 21/15 49/39
Corticosteroids treatment 54 (88.5%) 42 (93.3%) 96 (90.6%)
ACEi or ARB treatment 10 (16.4%) 12 (26.7%) 22 (20.8%)
Loop diuretics, thiazide diuretics or thiazide analogs treatment 21 (34.4%) 14 (31.1%) 35 (33.0%)
Iron supplementation 17 (27.9%) 8 (17.8%) 25 (23.6%)
Calcium supplementation 12 (19.7%) 7 (15.6%) 19 (17.9%)
Potassium supplementation 4 (6.6%) 5 (11.1%) 9 (8.5%)
Gastrointestinal disorders 45 (73.8%)* 22 (48.9%)* 50 (47%)
BMI body mass index, CsA cyclosporine, Tac tacrolimus, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers
*P<0.05, study group vs. control group
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the sodium salt of MPA. Corticosteroids (n=42) and CNI (n=
36) were the most frequently administered, and azathioprine
(n=16) and sirolimus (n=12) were also applied.
The study was approved by the Bioethical Committee at
Poznan University of Medical Sciences and is in accordance
with the Helsinki Declaration of 1975. Informed consent was
obtained from the patients prior to initiating the study.
Assessment of Plasma Bioelements
Plasma bioelements levels (Fe, Mg, Zn, and Cu) were
determined in 106 patients from both the study and control
groups. For all patients, the data on K, Na, and Ca
concentrations were obtained from hospital registers. The
determination of these bioelements is routinely performed
in the hospital laboratory at each of the patient’s transplant
clinic appointments.
For the plasma bioelement analyses, the patients’ blood
samples were taken after an overnight fast and collected in
ethylenediaminetetraacetic acid (EDTA) tubes, subsequent-
ly centrifuged to obtain plasma, and kept at −20°C until
analyzed.
The plasma concentrations of Fe, Zn, Cu, and Mg were
determined by flame atomic absorption spectrometry (AAS-
3, Carl Zeiss, Germany). In order to obtain concentrations
of the plasma bioelements which were within the ranges of
the calibration curves, the samples were diluted as follows:
for Fe, Zn, and Cu analyses, 0.01% aqueous solution of
Triton X-100 (Merck) was used, while for the Mg analysis,
aqueous solutions consisting of 0.01% Triton X-100
(Merck) and 0.05% lanthanum chloride (Merck) were used.
For Fe and Zn analyses, the calibration curves were
performed within the 0.5–2.5 ppm range (8.9–44.7 and 7.6–
38.2 μmol/L for Fe and Zn, respectively), while for Mg and
Cu analyses, the range was within 0.25–2.00 ppm (0.01–
0.08 mmol/L and 3.9–31.4 μmol/L for Mg and Cu,
respectively). The precision of the method was determined
with certified Human Multi-Sera Level 2 (Randox) and
amounted to 95.6%, 105.7%, 104.4%, and 99.6% for Fe,
Zn, Cu, and Mg, respectively.
Assessment of Dietary Intake
Each patient was given a diet history questionnaire to fill
out in order to estimate the 24-h food intake on the day
preceding the collection of the blood samples. On the basis
of the patients’ dietary history, the intake of the major and
trace elements was analyzed with Microsoft Access 2000
databases containing the extended version of the “Food
composition tables” [11].
Information on the supplementation of bioelements was
obtained from the diet history questionnaire as well as from
the patients’ hospital registers. For this purpose, a period of
1 month directly before the examination was taken into
consideration or in cases where the supplementation was
longer than 3 months, the 6 months preceding the
examination were considered.
Assessment of MPA Pharmacokinetic Profiles
The4-hMPApharmacokineticprofilesweredeterminedinthe
studygroup(n=61). Firstly, the blood samples were collected
before the morning dose of MMF (time 0), and subsequently
at 40 min, 1 h, 2, 3, and 4 h after MMF oral administration.
Blood samples were collected in EDTA tubes, centrifuged to
obtain plasma, and kept at −20°C until analyzed.
The pharmacokinetic profiles of MPA were determined
according to the high-performance liquid chromatography
method described elsewhere [12].
The following MPA pharmacokinetic parameters were
calculated: predose concentration (C0), maximum concen-
tration (Cmax), and area under the concentration–time curve
from 0 to 4 h (AUC0–4h ), using the linear trapezoidal rule.
Definitions of Normal Levels
The reference norms of the plasma mineral elements for
adult patients were assumed to be 137–145 mmol/L for Na,
3.6–5.0 mmol/L for K, 2.10–2.55 mmol/L for Ca (norms
according to which supplementation was adjusted, estab-
lished in the laboratory of the District Hospital in Poznań),
0.70–1.05 mmol/L for Mg, 10.6–28.3 μmol/L for Fe, 10.1–
16.8 μmol/L for Zn, and 11–24.4 μmol/L for Cu [13, 14].
For K and Na, the minimum dietary intake levels were
3,500 and 575 mg/day, respectively. Recommended dietary
intakes of 900 mg/day for Ca, 280–350 mg/day for Mg,
15–18 mg/day for Fe, 13–16 mg/day for Zn, and 2.0–
2.5 mg/day for Cu were assumed, following recommended
dietary allowances [15].
Statistical Analysis
All statistical tests were performed using Statistica software
version 8.0 (StatSoft), and P values lower than 0.05 were
considered significant. Normality was determined by the
Shapiro–Wilk test. The differences between variables were
estimated using the Mann–Whitney test and for normally
distributed data, Student’s t test was applied. The results are
presented as means±standard deviations. The correlations
of the data were tested using Pearson or Spearman
correlation analysis for normally and non-normally distrib-
uted data, respectively. Pearson’s chi-square test was used
for the evaluation of qualitative data.
Multivariate analysis of variance (MANOVA) and
multivariate regression analysis were applied to evaluate
138 Kamińska et al.the interactions between sex, age, post-transplant period,
MMF treatment, pharmacokinetics of MMF metabolite,
drugs co-administered (CNI and diuretics), and their
influence on the concentrations of plasma bioelements
studied. The nonsignificant models are not presented.
Results
Baseline Characteristics
The patients from the study and control groups did not
differ statistically in body weight, creatinine clearance,
creatinine concentration, co-administered drugs (cortico-
steroids, angiotensin-converting enzyme inhibitors [ACEi],
angiotensin II receptor blockers, diuretics such as loop and
thiazide diuretics or thiazide analogs), or in bioelement
supplementation.
The patients from the study group who were treated with
MMF and CsA did not differ in sex, age, period after
kidney transplantation, creatinine clearance, or creatinine
concentration from those patients treated with MMF and
Tac (data not shown). The MMF mean dose was lower
(1.06±0.27 g/day) when co-administered with Tac as
compared with the MMF mean dose co-administered with
CsA (1.73±0.35 g/day). Gastrointestinal disorders were
more frequently observed in study group (73.9% vs. 48.9%;
P=0.003).
Levels of Plasma Bioelements
In patients treated with MMF, significantly higher plasma
Fe, Zn, and Cu concentrations, as well as significantly
lower plasma Na concentrations were found relative to the
control group (Table 2).
In the study group, both hypernatremia (4.6% vs. 20.0%;
P=0.002) and Cu concentrations below the norm (6.9% vs.
40.0%; P<0.001) were less frequently observed than in the
control group.
Within the study group, in the subgroup of patients
treated with MMF and CsA, hypomagnesemia was less
frequently observed (44.0% vs. 87.0%; P=0.003), concur-
rent with significantly higher plasma concentrations of Mg
(P=0.004) and Cu (P=0.037) as compared to the subgroup
of patients treated with MMF and Tac (Table 2).
Considering all patients, plasma concentrations of Fe
exceeded the normal levels for this component in most
patients (59%). Mg and Zn plasma concentrations were
below the norms in 53% and 90% of the patients,
respectively (Fig. 1).
Bioelements and MPA Pharmacokinetic Parameters
There were significant positive correlations between the
MPA pharmacokinetic parameters (AUC0–4hand C0) and
the Mg concentrations, as well as negative correlations
between the MPA pharmacokinetic parameters (AUC0–4h ,
C0 and Cmax) and the Na and K concentrations (Table 3).
Patients with Mg concentrations within the norm
presented higher values of MPA pharmacokinetic parame-
ters such as MPA AUC0–4h(32.77±12.37 vs. 22.70±
7.91 mg h/L; P=0.002), MPA C0 (3.89±2.49 vs. 2.35±
1.58 mg/L; P=0.005) and MPA Cmax (16.49±6.18 vs.
11.53±4.92 mg/L; P=0.004) as compared to the patients
with hypomagnesemia.
Multivariate Regression Analysis
In multivariate regression analysis, the influence of MMF
treatment and its pharmacokinetic parameters in combina-
tion with some clinical factors (diuretics and CNI co-
administered, sex, and age) on plasma bioelement concen-
trations were evaluated. There was a significant influence
of MPA AUC0–4hand co-administered diuretics on K
Table 2 Concentrations of Major and Trace Elements in Relation to MMF and MMF with CNI Co-administered
Plasma mineral elements MMF P MMF in combination with P
Yes (n=61) No (n=45) CsA (n=28) Tac (n=24)
Potassium (mmol/L) 4.23±0.54 4.23±0.44 0.718 4.21±0.48 4.40±0.59 0.179
Sodium (mmol/L) 141.6±3.0 143.8±2.4 <0.001 141.79±3.15 141.19±2.75 0.180
Calcium (mmol/L) 2.47±0.14 2.43±0.16 0.467 2.46±0.13 2.44±0.15 0.609
Magnesium (mmol/L) 0.68±0.11 0.70±0.09 0.509 0.70±0.09 0.62±0.08 0.004
Iron (μmol/L) 32.9±9.4 28.7±9.4 0.032 33.68±10.29 33.53±9.70 0.857
Zinc (μmol/L) 8.26±2.14 7.50±1.53 0.030 8.09±1.82 8.31±1.71 0.435
Copper (μmol/L) 16.6±4.1 12.1±3.9 <0.001 17.96±4.35 15.89±4.25 0.037
MMF mycophenolate mofetil, CNI calcineurin inhibitors, CsA cyclosporine, Tac tacrolimus
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great statistical significance of this model, the partial P
value for MPA AUC0–4hwas statistically insignificant in
this model. Additionally, MMF administration and diuretic
treatment influenced Na concentration. In the studied
regression models, neither did ACEi treatment influence
K concentrations, nor did diuretic treatment influence Ca
and Mg concentrations. Mg concentration was significantly
dependent on MPA C0 and on CNI applied (P=0.011),
while Zn concentration was dependent on MMF treatment,
sex, and age (P=0.003). However, partial P values for MPA
C0 in Mg model and for MMF treatment in Zn model were
statistically insignificant. For Fe, Cu, and Ca, no statisti-
cally significant models were found in the multivariate
regression analysis.
Multivariate Analysis of Variance
On account of the differences in age, sex, and post-
transplant period between patients treated with MMF and
the control group (Table 1), the influence of these variables
on plasma bioelement concentrations was assessed. In
univariate analysis, higher Zn concentrations were observed
in men (8.42±2.14 vs. 7.50±1.68 μmol/L; P=0.042), in
younger patients (8.57±1.99 vs. 7.19±1.53 μmol/L; P<
0.001), as well as in patients with shorter post-transplant
periods (<5 years) in comparison to patients with longer
post-transplant periods (>5 years; 8.26±1.99 vs. 7.34±
1.84 μmol/L; P=0.015). However, despite the differences in
age, sex, and post-transplant period between the study and
control groups, the MANOVA for Zn did not show any
interactions between MMF treatment and the factors
described. While in the univariate analysis, patients
younger than 50 years presented statistically lower Na
concentrations (141.8±3.0 vs. 143.6±2.6 mmol/L; P=
0.007), the MANOVA did not show any interactions
between MMF treatment and the age of patients for either
Na or Zn. No influence of gender, age, or post-transplant
period on the concentrations of Fe, Mg, Ca, Cu, or K was
observed.
Dietary Intake and Supplementation
Current dietary intakes of the bioelements in daily food
ration were also analyzed in the patients included in the
study (Table 5). The dietary supplies of Ca, Mg, Fe, Zn, and
Cu were lower than recommended. Concomitantly, similar
intakes of the analyzed bioelements were observed in the
study group as compared to the control group as well as
within the study group with respect to CNI applied (P>
0.05). Nevertheless, mean Na intakes in all patients
included in the study exceeded the reference ranges by a
factor of four.
Discussion
In order to assess the impact of MMF on nutritional status
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Fig. 1 Plasma bioelements in relation to normal values in all studied
patients (n=106)
Table 3 Spearman Correlations between Bioelements and MPA Pharmacokinetic Parameters
MPA AUC0–4h(mg·h/L) MPA C0 (mg/L) MPA Cmax (mg/L) MMF mean dose (g/day)
rP r P r P r P
Potassium (mmol/L) −0.357 <0.001 −0.222 0.021 −0.240 0.012 −0.305 0.001
Sodium (mmol/L) −0.196 0.043 −0.268 0.005 −0.198 0.040 0.144 0.132
Calcium (mmol/L) 0.063 0.522 −0.136 0.161 0.183 0.057 −0.036 0.705
Magnesium (mmol/l) 0.323 0.016 0.403 0.002 0.225 0.098 0.346 0.008
Iron (μmol/L) −0.131 0.336 0.032 0.813 −0.192 0.157 −0.103 0.442
Zinc (μmol/L) 0.131 0.336 0.033 0.806 0.172 0.204 0.030 0.822
Copper (μmol/L) 0.123 0.365 0.044 0.747 0.049 0.720 0.150 0.262
MPA mycophenolic acid, C0 predose concentration, Cmax maximum concentration, AUC0–4harea under the plasma concentration—time curve
from 0 to 4 h
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compared. Subsequently, the influence of MMF metabolites
on plasma bioelement levels was analyzed.
The influence of MMF on plasma Na presented in our
study may be favorable, as Na intake in examined patients
exceeded the reference ranges fourfold, despite the fact that
Na restriction is normally recommended to renal transplant
recipients. Higher plasma Zn and lower plasma Na levels in
patients treated with MMF may have been related to the
patients’ younger ages and, in the case of Zn, additionally
to the shorter post-transplant period in the study group, as
compared to the control group. However, the multivariate
analysis of variance excluded the influence of the factors
described on these results. Additionally, the dietary intakes
of the analyzed bioelements were similar in both studied
groups, and no pharmacological supplementation of these
Table 4 Multivariate regression for some plasma bioelements
Clinical parameters Relation Partial P values Model P values Correlation coefficient r
Potassium (mmol/L)
MPA AUC0–4h(mg h/L) – 0.102 <0.001 0.554
Diuretics treatment
a (yes/no) Negative <0.001
Sodium (mmol/L)
MMF treatment (yes/no) Negative <0.001 <0.001 0.385
Diuretics treatment
a (yes/no) Positive 0.045
Magnesium (mmol/L)
MPA C0 (mg/L) – 0.120 0.011 0.437
MMF co-administered with CsA/Tac
b Positive 0.009
Zinc (μmol/L)
MMF treatment (yes/no) – 0.206 0.003 0.413
Sex (female/male)
c Negative 0.044
Age (years) Negative 0.022
MMF mycophenolate mofetil, MPA mycophenolic acid, AUC0–4harea under the plasma concentration—time curve from 0 to 4 h
aLoop diuretics, thiazide diuretics, or thiazide analogs
bCorrelation for CsA
cCorrelation for female
Table 5 Dietary intake of major and trace elements in relation to MMF and MMF with CNI co-administered
Mineral elements MMF
a MMF in combination with
a All group
Yes (n=61) No (n=45) CsA (n=28) Tac (n=24) (n=106)
Potassium (mg) 3282±1763 3544±1297 3087±1237 3247±2175 3391±1582
% minimum intake norm 93.8±50.4 101.2±37.0 88.2±35.3 92.8±62.2 96.9±45.2
Sodium (mg) 2282±1741 2438±1428 2524±2076 1722±784 2347±1611
% minimum intake norm 396.8±302.7 424.0±248.4 439.0±361.1 299.6±136.3 408.2±280.2
Calcium (mg) 534.9±295.3 731.9±747.0 453.2±178.1 558.3±303.1 617.3±538.5
%RDA 59.4±32.8 81.3±83.0 50.4±19.8 62.0±33.7 68.6±59.8
Magnesium (mg) 269.9±150.7 277.9±98.2 258.6±117.2 261.2±183.7 273.3±130.8
%RDA 78.9±40.4 84.9±31.0 75.2±30.1 78.0±50.9 81.4±36.7
Iron (mg) 12.35±6.25 12.30±4.50 12.20±4.86 11.39±7.19 12.33±5.56
%RDA 77.6±43.3 74.8±30.7 76.5±33.8 70.4±49.0 76.4±38.4
Zinc (mg) 9.66±4.14 9.65±4.06 9.57±3.97 8.63±3.60 9.66±4.08
%RDA 65.3±24.8 67.0±25.2 64.6±23.4 59.8±23.5 66.0±24.9
Copper (mg) 1.14±0.78 1.20±0.54 1.06±0.46 1.13±1.08 1.16±0.69
%RDA 51.0±34.6 53.9±24.4 47.6±20.3 50.8±47.8 52.2±30.7
MMF mycophenolate mofetil, CNI calcineurin inhibitors, CsA cyclosporine, Tac tacrolimus, RDA recommended daily allowance
aThe differences statistically insignificant
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that MMF may be the factor affecting Na and Zn balances.
The relation observed between MMF and plasma Na
concentration may partially confirm the results of Mattson
et al. [16] who observed the attenuation of blood pressure
elevation in sodium-sensitive rats treated with MMF and
fed excessively with sodium chloride. No research
concerning MMF influence on Cu and Zn plasma levels
has been found in the literature and the explanation of the
interaction mechanisms between MMF and plasma concen-
trations of the studied bioelements thus requires further
research. However, the results suggest that MMF may also
affect Cu balance, as higher concentrations—along with
less frequent occurrence of Cu levels below the norm—
were found in the study group, concomitantly with lower
than recommended dietary supply in all patients.
Although the patients treated with MMF demonstrated
similar plasma K as compared to the control group, there
were slightly significant negative correlations between K
levels and all MPA pharmacokinetic parameters, as well as
the MMF dose. The correlation concerning K, as well as
Na, may be related to the decreased absorption of these
electrolytes in patients treated with MMF, probably due to
gastrointestinal disorders which were more frequent in the
study group. Plasma K is routinely monitored and supple-
mented in renal transplant patients, which may be the
reason for the occurrence of similar K levels in both the
study and control groups. In this case too, no similar studies
concerning MMF have been found in the literature.
Our study did not show any differences in Ca concen-
trations between the study and control groups. We found
only one article concerning Ca concentrations in patients
treated with MMF. The authors observed decreased urinary
excretion of Ca during MMF treatment, in combination
with CsA and prednisone; however, the study involved a
small number of patients (n=20) and the results were
compared to normal values [17]. As CsA is known to
decrease Ca concentrations in patients’ serum by increasing
the urinary excretion of this bioelement [18], the results of
Khosroshahi et al. [17] suggest that MMF may reduce the
Ca excretion.
Higher plasma Fe in the group treated with MMF along
with Fe concentrations above the normal level, regardless of
the immunosuppressive drug administered, may be due to the
frequency of Fe supplementation (about 28% of study group
vs. 18% of control group, P>0.05). This supplementation is
applied to prevent anemia, which is one of the most frequent
side effects during immunosuppressive therapy [19]. The
high plasma Fe in all patients included in our study was
related neither to gender nor to the patients’ current dietary
intake as we observed low and insufficient dietary supplies
of Fe in their food rations (76.4% of Fe intake norm). The
results indicate that the introduction of Fe monitoring may be
favorable and may assist in rapid diet correction as well as in
adjusting pharmacological supplementation.
AlthoughwefoundsomepositivecorrelationsbetweenMg
plasma concentrations and MPA pharmacokinetic parameters,
no similar studies concerning MMF and Mg have been found
in the literature. Further research is thus required in order to
explain the cause of the correlations obtained. Our study
showed lower plasma levels of Mg in patients treated with
MMF and Tac, ascomparedtopatientstreated withMMFand
CsA. Numerous studies have shown that CNI leads to
decreased Mg concentration [2, 20–26], mainly due to Mg
loss with urine [21, 22]. In our study, the differences in
plasma Mg between patients treated with MMF and CsA in
comparison to MMF and Tac may be caused by the different
daily doses of MMF applied in these two subgroups. Our
results suggest that in patients treated with CNI, the
introduction of MMF into immunosuppressive therapy may
be beneficial by reducing the risk of hypomagnesemia as
MMF correlates positively with Mg concentration.
In all patients included in the study, the deviations from
the normal levels of plasma bioelements were observed.
Insufficiency of plasma Zn and Mg, as well as too high
concentrations of Fe—which is often excessively supple-
mented after kidney transplantation, were most frequently
observed. Zn deficiency may have been caused by
corticosteroid treatment (about 91% of patients) as cortico-
steroids increase the excretion of Zn, K, and Ca. Lower
than normal Mg concentrations may have been the result of
frequent (about 33%) diuretic co-administration as these
drugs are known to increase Mg, K, and Na excretion.
Importantly, neither Zn nor Mg was routinely monitored in
patients included in the study in contrast to K, Na, and Ca.
In conclusion, in our study, MMF treatment favorably
affected Cu and Zn levels by increasing their plasma
concentrations and favorably affected Na levels by decreas-
ing its plasma concentration. However, some of these
differences, despite being statistically significant, may be
irrelevant in clinical practice. Yet the results suggest that
MMF does not limit the absorption of bioelements studied
with the exception for Na. The concentrations of Na, K, and
Ca are routinely determined in post-transplant patients. It is,
however, reasonable to also monitor other plasma bioele-
ments, such as Mg, Zn, and Fe, as the concentrations of
these components diverged frequently from normal levels.
This may enable early diet and supplement adjustment in
renal transplant recipients.
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